Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line <i>Helicobacter pylori</i> eradication: a double-blind randomized controlled trial.

ABSTRACT:

Background

Helicobacter pylori eradication reduces the risk of peptic ulcer disease and gastric cancer. In Chile, the effectiveness of standard triple therapy has dropped below 80%. We compared optimized bismuth quadruple therapy: esomeprazole 40 mg three times a day, amoxicillin 1 gr three times a day, metronidazole 500 mg three times a day, and bismuth subsalicylate 369 mg three times a day for 14 days, and standard triple therapy omeprazole 20 mg twice a day, amoxicillin 1 gr twice a day, and clarithromycin 500 mg twice a day for 14 days in a Chilean population.

Methods

Randomized double-blind clinical trial. 127 treatment-naïve individuals with confirmed active H. pylori were recruited. The primary outcome was successful H. pylori eradication,

SUBMITTER: Medel-Jara PA 

PROVIDER: S-EPMC12681926 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature